Profile data is unavailable for this security.
About the company
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
- Revenue in USD (TTM)0.00
- Net income in USD-60.18m
- Incorporated2021
- Employees14.00
- LocationZura Bio Ltd4225 Executive Square, Suite - 600SAN DIEGO 92037United StatesUSA
- Phone+1 (858) 247-0520
- Websitehttps://zurabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AC Immune SA | 16.17m | -59.23m | 342.23m | 133.00 | -- | 1.95 | -- | 21.17 | -0.701 | -0.701 | 0.1904 | 1.77 | 0.0803 | -- | 1.92 | 121,544.00 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
Foghorn Therapeutics Inc. | 33.90m | -92.95m | 344.14m | 116.00 | -- | -- | -- | 10.15 | -2.21 | -2.21 | 0.8046 | -2.29 | 0.108 | -- | -- | 292,206.90 | -29.61 | -31.35 | -35.75 | -35.69 | -- | -- | -274.23 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
Nautilus Biotechnology Inc | 0.00 | -67.44m | 346.98m | 163.00 | -- | 1.39 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Tenaya Therapeutics Inc | 0.00 | -124.58m | 347.05m | 140.00 | -- | 2.19 | -- | -- | -1.65 | -1.65 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -57.91 | -- | -63.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
Precigen Inc | 5.44m | -96.91m | 348.34m | 202.00 | -- | 3.56 | -- | 64.04 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
Sutro Biopharma Inc | 154.07m | -114.96m | 348.44m | 300.00 | -- | 2.71 | -- | 2.26 | -1.89 | -1.89 | 2.53 | 1.57 | 0.4047 | -- | 7.48 | 510,149.00 | -30.20 | -25.48 | -36.94 | -29.75 | -- | -- | -74.62 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
Tourmaline Bio Inc | 0.00 | -32.94m | 349.56m | 44.00 | -- | 0.9871 | -- | -- | -5.35 | -5.35 | 0.00 | 13.81 | 0.00 | -- | -- | 0.00 | -12.39 | -- | -12.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Zura Bio Ltd | 0.00 | -60.18m | 351.53m | 14.00 | -- | 3.94 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Fibrobiologics Inc | 0.00 | -22.53m | 351.73m | 10.00 | -- | -- | -- | -- | -1.03 | -1.03 | 0.00 | -0.1181 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
ADC Therapeutics SA | 68.62m | -227.23m | 353.01m | 273.00 | -- | -- | -- | 5.14 | -2.77 | -2.77 | 0.8368 | -2.35 | 0.1769 | 0.2683 | 2.91 | 251,351.60 | -56.99 | -48.41 | -69.99 | -55.63 | 93.30 | -- | -322.09 | -308.62 | 4.35 | -4.14 | 1.85 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
Aura Biosciences Inc | 0.00 | -78.65m | 354.73m | 88.00 | -- | 1.70 | -- | -- | -1.86 | -1.86 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -35.66 | -- | -37.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
Q32 Bio Inc | 354.00k | -83.09m | 355.40m | 39.00 | -- | 7.28 | -- | 1,003.95 | -25.73 | -25.73 | 0.1182 | 4.09 | 0.002 | -- | -- | 50,571.43 | -34.17 | -34.98 | -40.05 | -37.92 | -- | -- | -16,901.98 | -971.76 | -- | -- | 0.2039 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
Cerus Corp | 191.72m | -31.56m | 356.84m | 288.00 | -- | 7.22 | -- | 1.86 | -0.1742 | -0.1742 | 1.06 | 0.2671 | 0.9623 | 1.92 | 8.03 | 665,680.60 | -15.91 | -25.99 | -24.20 | -40.62 | 61.73 | 61.90 | -16.53 | -35.81 | 1.72 | -2.16 | 0.6287 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
Amarin Corporation plc (ADR) | 277.46m | -52.61m | 358.20m | 275.00 | -- | 0.6559 | -- | 1.29 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
Jasper Therapeutics Inc | 0.00 | -63.93m | 359.34m | 45.00 | -- | 3.17 | -- | -- | -5.60 | -5.60 | 0.00 | 7.51 | 0.00 | -- | -- | 0.00 | -48.30 | -- | -51.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
Shattuck Labs Inc | 2.72m | -85.08m | 362.81m | 75.00 | -- | 2.81 | -- | 133.63 | -1.93 | -1.93 | 0.0608 | 2.71 | 0.0168 | -- | -- | 36,200.00 | -52.52 | -29.14 | -57.94 | -32.42 | -- | -- | -3,133.63 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
Holder | Shares | % Held |
---|---|---|
Athanor Capital LPas of 25 Mar 2024 | 4.80m | 11.02% |
Deep Track Capital LPas of 18 Apr 2024 | 3.33m | 7.63% |
RA Capital Management LPas of 22 Apr 2024 | 3.22m | 7.38% |
Suvretta Capital Management LLCas of 31 Mar 2024 | 2.85m | 6.54% |
Great Point Partners LLCas of 31 Mar 2024 | 2.76m | 6.33% |
Armistice Capital LLCas of 31 Mar 2024 | 1.65m | 3.78% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 993.22k | 2.28% |
Citadel Advisors LLCas of 31 Mar 2024 | 681.10k | 1.56% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 559.97k | 1.29% |
Geode Capital Management LLCas of 31 Mar 2024 | 487.13k | 1.12% |